Business Overview: OraSure Technologies, Inc. (NASDAQ: OSUR)

---

Executive Summary

OraSure Technologies, Inc. develops, manufactures, and sells point-of-care diagnostic tests and sample-collection/management products, best known for the OraQuick® rapid oral-fluid HIV test. Headquartered in Bethlehem, Pennsylvania, the company operates as a single business unit spanning infectious-disease diagnostics (HIV, hepatitis C, Ebola, Marburg) and a sample management/genomics line (DNA Genotek's Oragene® and ORAcollect® saliva collection kits, Colli-Pee® urine collection, and OMNIgene® microbiome stabilization products) sold to labs, public health agencies, consumer genetics companies, and researchers worldwide.

OraSure's revenue history over the last few years is a cautionary tale in platform concentration: the company became a major supplier of at-home COVID-19 antigen tests (InteliSwab®) under a 2021 U.S. Department of Defense contract, which pushed revenue to roughly $258 million in 2023. As COVID testing demand collapsed, InteliSwab revenue fell to about $45 million in 2024 and essentially to zero (~$0.6 million) in 2025, dragging total 2025 revenue down to roughly $115 million — a decline of about 38% year-over-year — and widening net losses. The company has responded by exiting substance-abuse testing (announced November 2024) and acquiring new assets — BioMedomics (SickleSCAN® sickle-cell test, November 2025) and Sherlock Biosciences (molecular/CRISPR-adjacent self-test platform, including a chlamydia/gonorrhea self-test submitted to the FDA in December 2025) — to rebuild a pipeline around its legacy HIV franchise and genomics business.

OraSure matters less for its current scale than for its durable niche: it holds FDA approval for the only over-the-counter, oral-fluid HIV self-test sold in the United States, a position it has held for well over a decade, and its DNA Genotek saliva-collection kits are deeply embedded in large academic and commercial genomics research pipelines.

---

1. Core Business Model & How They Work

OraSure designs and manufactures rapid diagnostic tests and biological sample-collection devices, sells them through a mix of direct sales (U.S. public health and sample management) and distributors (international diagnostics, some U.S. hospital/physician channels), and collects royalties/service revenue on some genomics partnerships. The economics are driven by regulatory approval (FDA, WHO prequalification), manufacturing scale, and reimbursement/public-health funding cycles.

[ R&D / Device Design ] ➞ [ Regulatory Clearance (FDA PMA/510(k)/EUA, WHO PQ) ]
        ➞ [ Manufacturing (Bethlehem, PA; Ottawa/Canada; Thailand contract assembly) ]
        ➞ [ Distribution (Direct sales, distributors, OTC retail/online) ]
        ➞ [ End Users (Labs, clinics, public health agencies, consumers, researchers) ]
        ➞ [ Recurring Replenishment / New Program Wins ]

Key Operational Drivers

1. Regulatory moat on core franchise: OraQuick® HIV self-test is, per the company's own 10-K disclosure, the only over-the-counter oral-fluid HIV test approved for sale in the U.S. — a position built on an FDA premarket approval that would be costly and time-consuming for a new entrant to replicate.
2. Public-sector and program-driven demand: A large share of historical revenue has come from government and public-health programs (U.S. DoD COVID contract, African public health HIV testing programs), which is lucrative when won but creates lumpy, program-dependent revenue.
3. Bolt-on M&A to rebuild the pipeline: Recent acquisitions of BioMedomics (sickle-cell point-of-care test) and Sherlock Biosciences (molecular self-test platform, including a CT/NG self-test under FDA review) are explicit attempts to diversify beyond the HIV/COVID-dependent product set.
4. Manufacturing consolidation: The company is consolidating production at its Opus Way facility in Bethlehem, PA, after scaling up InteliSwab capacity during the pandemic — now right-sizing fixed costs as COVID volume has disappeared.

---

2. Business Segments

OraSure discloses only one reportable business/operating segment in its 10-K, but its revenue is meaningfully split across distinct product lines that behave differently. Rather than invent formal "segments" the company does not report, the breakdown below reflects its disclosed product-line revenue.

                    OraSure Technologies, Inc. (one reporting unit)
        ┌───────────────────────────┬───────────────────────────┐
        │  Infectious Disease Dx    │   Sample Mgmt / Genomics   │
        │  (OraQuick® HIV/HCV,      │   (DNA Genotek, Colli-Pee®,│
        │   InteliSwab® COVID,      │    OMNIgene®)              │
        │   SickleSCAN®, Sherlock)  │                            │
        └───────────────────────────┴───────────────────────────┘

Infectious Disease Diagnostics

Anchored by OraQuick® HIV tests (~$50 million of 2025 revenue), plus OraQuick HCV, Syphilis Health Check™ (distributed for Diagnostics Direct), an Ebola test, a Marburg test in development, the newly acquired SickleSCAN® sickle-cell test, and the now-near-zero InteliSwab® COVID-19 line (down from ~$257 million in 2023 to ~$0.6 million in 2025 as pandemic-era government buying ended).

Sample Management / Genomics

DNA Genotek's Oragene® and ORAcollect® saliva collection devices for DNA/RNA, Colli-Pee® volumetric urine collection, HEMAcollect™ • PROTEIN blood collection tubes (launched July 2025), and OMNIgene® microbiome stabilization products, sold to consumer genetics firms, academic/research institutions, and pharmaceutical and agricultural customers. This line generated roughly $31.5 million in 2025, down modestly from $44.9 million in 2024.

---

3. Product Portfolio

---

4. Competitive Landscape

OraSure's 10-K does not name specific competitors by name, describing the diagnostics and life-sciences tools industries generally as "intensely competitive" against companies that are "often much larger." Based on product-line dynamics disclosed and industry structure:

• HIV/HCV point-of-care testing: Competes with lab-based automated blood tests (run by large diagnostics players such as Abbott, Roche, and Bio-Rad) and, outside the U.S., with other rapid blood-based HIV/HCV tests often priced at or below OraSure's oral-fluid products. OraSure's defensible niche is being the only OTC oral-fluid HIV test cleared in the U.S.
• COVID-19 antigen/molecular testing: A crowded, now-shrinking field including Abbott (BinaxNOW), Quidel/QuidelOrtho, and numerous molecular/EUA-authorized entrants; OraSure has little differentiated advantage here and InteliSwab revenue has largely evaporated as the category has commoditized and demand has fallen.
• Genomics sample collection: Competes with blood collection tube makers and buccal swab/collection-device suppliers (e.g., Qiagen, Thermo Fisher/Invitrogen-adjacent collection products), some priced lower than DNA Genotek's kits; OraSure's edge is being an established, validated collection standard already built into customers' lab protocols.
• Microbiome sample stabilization: Competes largely against in-house/freezing-based solutions developed by researchers themselves rather than other commercial vendors — OraSure describes itself as one of the few vendors offering a standardized commercial alternative.
• Molecular self-testing (new, via Sherlock): An emerging category where larger molecular diagnostics companies (Roche, Hologic, Cepheid/Danaher) have far greater R&D scale; OraSure's Sherlock-derived platform is unproven commercially.

                 DIAGNOSTICS POSITIONING
┌───────────────────────────────────────────────────┐
│ High                                                │
│   ▲         [OraQuick HIV OTC]                     │
│   │         (category monopoly, low scale)         │
│   │                                                 │
│  Niche                              [Abbott/Roche]  │
│ Defensibility                       (broad, massive │
│   │                                  scale)         │
│   │         [InteliSwab COVID]                      │
│   ▼         (low differentiation, commoditized)     │
│ Low ────────────────────────────────────────────▶   │
│      Low                Manufacturing Scale    High │
└───────────────────────────────────────────────────┘

---

5. Strategic Strengths & Risks

Strategic Strengths (The Moat)

• Regulatory exclusivity on OraQuick® HIV: Being the only FDA-approved OTC oral-fluid HIV self-test in the U.S. is a real, durable regulatory barrier — a competitor would need its own PMA approval, which is slow and costly, to contest this niche directly.
• Embedded genomics collection standard: DNA Genotek's saliva and microbiome collection devices are built into established academic, consumer-genetics, and pharma research protocols, creating real (if modest) switching friction once validated into a study or workflow.
• Public-health and government relationships: Decades of supplying HIV tests to African public-health programs and U.S. agencies (and the BARDA/DoD-funded Ebola, Marburg, and historical InteliSwab programs) give OraSure incumbency advantages when bidding for future outbreak-response or public-health testing contracts.

Strategic Risks

• Revenue concentration and volatility: The collapse of InteliSwab COVID revenue (from ~$257M in 2023 to ~$0.6M in 2025) demonstrates how exposed OraSure is to single-program, government-driven demand spikes that can disappear entirely.
• Sustained net losses and shrinking scale: Full-year 2025 revenue fell roughly 38% to about $115 million with a net loss of roughly $68.7 million, raising questions about the path back to profitability now that COVID volume is gone.
• Unproven new pipeline: Growth hopes now rest on recently acquired, largely unproven assets — Sherlock Biosciences' molecular self-test platform (still pending FDA review as of this writing) and BioMedomics' SickleSCAN® — neither of which has an established revenue track record inside OraSure.
• Customer concentration decline, exit of substance-abuse testing: The exit from substance-abuse testing (announced November 2024, wound down through mid-2025) removes a historically meaningful product line, and one non-commercial customer that was 63% of revenue in 2023 and 24% in 2024 fell to just 3% in 2025 — showing both program dependence and the difficulty of replacing lost volume.
• Intensifying competition from larger players: The company's own 10-K flags that competitors are "often much larger," with expected cost pressure, industry consolidation, and tighter reimbursement ahead.

---

6. Financial Overview

---

7. Summary Conclusion

OraSure Technologies occupies a real but narrow regulatory moat — it is the only company selling an over-the-counter, oral-fluid HIV self-test in the United States, and its DNA Genotek genomics collection products are genuinely embedded in research customers' workflows. That durable niche, however, sits inside a company whose top line was badly distorted by a pandemic-era COVID testing windfall that has now almost entirely disappeared, leaving reported revenue down roughly 38% in 2025 and losses widening sharply.

The company's forward story is now a bet on whether recently acquired, unproven assets — the Sherlock Biosciences molecular self-test platform (pending FDA clearance for a chlamydia/gonorrhea self-test) and BioMedomics' SickleSCAN® sickle-cell test — can be commercialized fast enough to rebuild a growth pipeline around the stable but modest-sized legacy HIV and genomics franchises, before cash reserves and investor patience run out.